Clinical trials: Risk of Venous Thrombosis
Pulmonary Embolism, Deep Vein Thrombosis
The Angel® Catheter Pivotal Clinical Trial
The primary objective of this multicenter, prospective, single arm clinical trial is to evaluate the safety and effectiveness of the Angel® Catheter in subjects at high risk of PE, and with recognized contraindications to…
- Conditions
- Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism, Trauma
- Trial name
- NCT02186223
- Testing
- The Angel® Catheter
- Where
- 21 sites in United States
- Volunteers
- 172 people
- Sponsor
- BiO2 Medical
Venous Thromboembolism, Risk Factor, Cardiovascular
Distribution of Risk Factors for Venous Thromboembolism in Blood Donors
Venous thromboembolism occurs with an incidence of about 1 per 1000 per year in adults . The main consequences are death, recurrence, post-thrombotic syndrome and major bleeding due to anticoagulation.
- Conditions
- Venous Thromboembolism, Risk Factor, Cardiovascular, Blood Type
- Trial name
- ANEMONE (NCT03282747)
- Testing
- no intervention
- Where
- Italy
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Casa Sollievo della Sofferenza IRCCS
Contraception, Female Contraception
Relative Risks for Non-fatal Venous Thromboembolism, Ischemic Stroke and Myocardial Infarction in Users of ORTHO EVRA(Norelgestromin and Ethinyl Estradiol Contraceptive Patch) Compared to Levonorgestrel-containing Oral Contraceptives.
This study uses the PharMetrics and MarketScan US health care insurance claims database to estimate relative risks for non-fatal venous thromboembolism (including cerebral venous sinus thrombosis), ischemic stroke, and acute…
- Conditions
- Contraception, Female Contraception, Fertility Control
- Trial name
- NCT00511784
- Volunteers
- 440 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Venous Thromboembolism
Use of Oral Contraceptives (OCs) Containing Dienogest and Risk of Venous Thromboembolism
The objective of this study is to compare the risk of venous thromboembolism (VTE) of oral contraceptives with non-use, focusing specifically on Valette® compared to other users of low estrogen dose combined oral contraceptives.
- Trial name
- NCT00523614
- Where
- Germany
- Volunteers
- 3,400 people
- Sponsor
- Center for Epidemiology and Health Research, Germany
Cerebral Venous Sinus Thrombosis
MENA Regional Endovascular Intervention for Venous Cerebral Venous Sinus Thrombosis
REVIVE-CVST is a multicenter, prospective, randomized, open-label, blinded-endpoint (PROBE) trial evaluating whether early endovascular thrombectomy (EVT) combined with standard anticoagulation improves outcomes compared to…
- Trial name
- REVIVE-CVST (NCT07548346)
- Testing
- Endovascular Thrombectomy, Anticoagulation Therapy
- Where
- 14 sites in Egypt, Jordan and 6 more
- Volunteers
- 440 people
- Sponsor
- Middle East North Africa Stroke and Interventional Neurotherapies Organization
Pulmonary Embolism
Crux Biomedical Vena Cava Filter Study - United States
The purpose of this study is to determine if the Crux Vena Cava Filter System is safe and effective in preventing pulmonary embolism.
- Trial name
- RETRIEVE 2 (NCT01120509)
- Testing
- Inferior Vena Cava Filter
- Where
- 17 sites in United States
- Volunteers
- 88 people
- Sponsor
- Crux Biomedical
Venous Thromboembolism
Identification of New Genetic Markers of Risk of Venous Thromboembolism Recurrence by Analyzing Whole Genome
Venous thromboembolism (VTE) is a common and potentially fatal disease. It is considered a chronic disease with a recurrence rate of 30% at 10 years. Reduce the risk of recurrence is a serious public health issue.
- Trial name
- NCT02904967
- Testing
- Extra Blood Draw
- Where
- France
- Volunteers
- 221 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Venous Thromboembolism
Platelet FcGammaRIIa and Risk of Venous Thromboembolism in Cancer
Thrombosis is common and contributes significantly to morbidity and mortality in patients with cancer. At least 20% of patients with cancer develop venous thromboembolism (VTE) and another 5% will experience acute arterial…
- Trial name
- NCT05240508
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- University of Vermont
Deep Vein Thrombosis, Pulmonary Embolism
3 Screen Electronic Alert
Evaluation of physician responses to BICS-Clinical Information 3-screen alerts that informs the clinician that his/her patient may be eligible for thromboprophylaxis.
- Conditions
- Deep Vein Thrombosis, Pulmonary Embolism, Cancer
- Trial name
- NCT00550082
- Where
- United States
- Volunteers
- 880 people
- Sponsor
- Brigham and Women's Hospital
Venous Thromboembolism
Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism
Apixaban and rivaroxaban have been compared to standard therapy for treatment of acute symptomatic venous thromboembolism (VTE) in randomized controlled trials (RCTs), and are both approved by Health Canada.
- Trial name
- COBRRA (NCT03266783)
- Testing
- Apixaban, Rivaroxaban
- Where
- 19 sites in Australia, Canada and 1 more
- Volunteers
- 2,760 people
- Sponsor
- Ottawa Hospital Research Institute
Venous Thromboembolism, Bleeding
Avoiding Risks of Thrombosis and Bleeding in Surgery (ARTS) Trial
Avoiding Risks of Thrombosis and bleeding in Surgery (ARTS) trial is a pragmatic, international, multicenter, randomized controlled open label trial comparing a direct oral anticoagulant (DOAC) - oral factor Xa inhibitor apixaban…
- Trial name
- ARTS (NCT06523959)
- Testing
- Apixaban 2.5 MG
- Where
- Finland
- Volunteers
- 5,436 people
- Sponsor
- Clinical Urology and Epidemiology Working Group
Deep Vein Thrombosis (DVT)
Nursing-Led Deep Vein Thrombosis Prevention in Neurosurgery
The goal of this clinical trial is to see if a nurse-led program (early movement, leg-sleeve squeezes, and blood tests) can prevent dangerous leg blood clots in adults who have just had brain or spine surgery.
- Trial name
- NCT07330661
- Testing
- nurse-led program (early movement, leg-sleeve squeezes, and blood tests)
- Where
- China
- Volunteers
- 1,286 people
- Sponsor
- West China Hospital
Thrombosis, Venous
Hemorrhage Risk Prescribed Arixtra
Arixtra (fondaparinux sodium) was the first selective Factor Xa inhibitor to be marketed. As with all anticoagulants, an important adverse event associated with Arixtra use is haemorrhage.
- Trial name
- NCT01064362
- Testing
- Fondaparinux sodium, Low molecular weight heparin (LMWH)
- Volunteers
- 13,442 people
- Sponsor
- GlaxoSmithKline
Venous Thromboembolism, Liver Transplantation
Risk Factors and a nOmogram of Venous thromboEmbolism in Patients After liveR Transplantation(ROVER Study)
Liver transplantation is currently an effective treatment for end-stage liver disease. The high incidence of thrombotic related complications in the early postoperative period after orthotopic liver transplantation(OLT) has been…
- Trial name
- NCT05209048
- Where
- China
- Volunteers
- 356 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Venous Thromboembolism, Neurosurgery
Prospective Validation of Clinical Prediction Model for Venous Thromboembolism Following Neurosurgery
Validation of Clinical Prediction Model for Venous Thromboembolism Following Neurosurgery: A Multicenter, Prospective, and Cohort Study
- Conditions
- Venous Thromboembolism, Neurosurgery, Risk Assessment
- Trial name
- NCT05860790
- Testing
- Clinical Prediction Model for Venous Thromboembolism Following Neurosurgery
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Capital Medical University
Venous Thromboembolism (VTE), Cancer
Vortosiran for VTE Prevention
Blood clots remain a serious cause of illness and death. Long-term treatment and prevention of these clots with blood thinners is often limited by bleeding risk, drug interactions, and daily dosing, leading many patients to stop…
- Conditions
- Venous Thromboembolism (VTE), Cancer, Pulmonary Embolism (Diagnosis)
- Trial name
- NCT07850453
- Testing
- Vortosiran
- Where
- 30 sites in Bulgaria, France and 2 more
- Volunteers
- 150 people
- Sponsor
- Ribocure Pharmaceuticals AB
Hepatocellular Carcinoma
The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) Versus Adjuvant Transarterial Chemoembolization (TACE) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.
To compare the impact on recurrence risk of adjuvant TAI and adjuvant TACE for patients with HCC and PVTT after hepatectomy.
- Trial name
- NCT03192644
- Testing
- TAI, TACE, epidoxorubicin and cisplatin and lipiodol
- Where
- China
- Volunteers
- 162 people
- Sponsor
- Sun Yat-sen University
Venous Thromboembolism
Effect of Intravenous Continuous Infusion Heparin on Rates of Venous Thromboembolism in High-Risk, Critically Ill Patients
The primary purpose of this study is to demonstrate that a continuous infusion of intravenous (IV) heparin (UFH) for Venous thromboembolism (VTE) prophylaxis will restore prophylactic levels of heparin in high-risk critically ill…
- Trial name
- NCT02707263
- Testing
- intravenous continuous infusion of heparin (IV UFH), Subcutaneous Heparin
- Where
- United States
- Sponsor
- NYU Langone Health
Thromboembolic Disease
The Correlation of Lewis Antigens With VTE
The goal of this observational study is to learn if certain factors in a person's blood are linked to a history of venous thromboembolic disease (VTED), which includes conditions like deep vein thrombosis.
- Trial name
- NCT07402005
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Larissa University Hospital
Venous Thromboembolism
Retrospective Study to Review Patients at Risk for VTE at Hospital Discharge
An investigator initiated study exploring VTE prophylaxis at the time of hospital discharge.
- Trial name
- NCT00604370
- Volunteers
- 2,500 people
- Sponsor
- Brigham and Women's Hospital